Opinion

Video

Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials

Dr. Gandhi and Dr. Clifton discuss incorporating imlunestrant plus abemaciclib into treatment sequencing for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (BC), considering factors such as ESR1 mutation status, prior CDK4/6 inhibitor (CDK4/6i) use, and visceral metastases, while also highlighting key trials of selective estrogen receptor degraders (SERDs), including SERENA-2 and OPERA-01.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • Based on the data seen in the EMBER-3 trial, how do you anticipate incorporating imlunestrant plus abemaciclib into your treatment sequencing for patients with HR+/HER2– metastatic BC? In which patients and in which line of therapy would you consider using this combination?
      • Based on subgroup data, how might you consider these factors in your clinical decision-making?
        • ESR1 mutation vs wild type
        • Prior CDK4/6i
        • Duration of prior CDK4/6i
        • Presence of visceral metastases
    • Please highlight other trials of note investigating SERDs in HR+/HER2– BC:
      • SERENA-2: camizestrant vs fulvestrant
      • OPERA-01: palazestrant vs standard-of-care endocrine therapy
      • Any others (eg, EMBER-4, SERENA-4,ELEVATE, etc)